Pediatrix Medical Group has had an impressive run over the past six months as its shares have beaten the S&P 500 by 31.6%. The stock now trades at $23.07, marking a 36.2% gain. This performance may have investors wondering how to approach the situation.
Is there a buying opportunity in Pediatrix Medical Group, or does it present a risk to your portfolio? Dive into our full research report to see our analyst team’s opinion, it’s free.
Why Is Pediatrix Medical Group Not Exciting?
We’re glad investors have benefited from the price increase, but we're swiping left on Pediatrix Medical Group for now. Here are three reasons there are better opportunities than MD and a stock we'd rather own.
1. Long-Term Revenue Growth Disappoints
Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Regrettably, Pediatrix Medical Group’s sales grew at a tepid 2% compounded annual growth rate over the last five years. This was below our standards.
2. Projected Revenue Growth Shows Limited Upside
Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite.
Over the next 12 months, sell-side analysts expect Pediatrix Medical Group’s revenue to stall. While this projection suggests its newer products and services will catalyze better top-line performance, it is still below average for the sector.
3. New Investments Fail to Bear Fruit as ROIC Declines
A company’s ROIC, or return on invested capital, shows how much operating profit it makes compared to the money it has raised (debt and equity).
We like to invest in businesses with high returns, but the trend in a company’s ROIC is what often surprises the market and moves the stock price. Unfortunately, Pediatrix Medical Group’s ROIC averaged 4.7 percentage point decreases each year over the last few years. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between.
Final Judgment
Pediatrix Medical Group isn’t a terrible business, but it isn’t one of our picks. With its shares beating the market recently, the stock trades at 9.9× forward P/E (or $23.07 per share). While this valuation is optically cheap, the potential downside is big given its shaky fundamentals. We're fairly confident there are better investments elsewhere. We’d recommend looking at one of our all-time favorite software stocks.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
